A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
CA 2327339 A1 · Owner: Thomas Jefferson University · Inventors: Berd, David
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a method of inducing an anti-tumor response against a metastatic melanoma by administering an effective amount of a composition comprising at least one of the following: (i) a hapten-modified syngeneic mammalian melanoma cell substantially in a no growth phase (ii) a , hapten-modified melanoma cell membrane (iii) a peptide isolated from said , hapten-modified melanoma cell or membrane and (iv) a T cell capable of mediating an anti-tumor response such as for example regression of a melanoma. The metastatic melanoma treated according to the present invention includes metastatic melanoma which is limited to the lung and is preferably a small lung …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 9, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.